文献速递消化道肿瘤放疗胸部肿瘤放疗

食管癌切除术后并发症:新辅助放化疗与新辅助化疗比较的单机构队列研究

Postoperative complications after esophagectomy for cancer, neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy: A single institutional cohort study.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-03-04

本研究基于单机构食管癌手术数据库,比较2008年10月至2020年3月间接受新辅助化疗(93例)与新辅助放化疗(181例)后行食管癌切除术患者的30天术后并发症。结果显示,在化疗基础上增加放疗未增加术后并发症发生率,肺和心脏的放疗剂量/体积参数与术后并发症无关,但含紫杉类化疗方案与术后并发症发生率增加相关。

要点

  • 新辅助化疗基础上增加放疗未增加食管癌切除术后并发症发生率。
  • 肺和心脏的放疗剂量参数与术后并发症无关。
  • 含紫杉类化疗方案(无论是否联合放疗)与术后并发症发生率增加相关。

核心结论

  • 在本队列中,新辅助化疗基础上增加放疗与术后并发症无关。
  • 含紫杉类化疗方案(联合或不联合放疗)与术后并发症相关。

研究设计与样本

  • 基于单机构食管癌手术数据库的队列研究,研究期为2008年10月至2020年3月。
  • 接受新辅助放化疗的患者与接受新辅助化疗的患者进行比较,并分析肺和心脏的剂量/体积参数。
  • 主要结局为30天术后并发症。

主要发现

  • 研究期间共274例患者接受食管癌手术,其中新辅助化疗后93例,新辅助放化疗后181例。
  • 计划靶区处方放疗剂量中位数为41.4 Gy,平均肺剂量中位数为6.2 Gy,平均心脏剂量中位数为20.3 Gy。
  • 新辅助化疗基础上增加放疗未增加术后并发症发生率。
  • 肺和心脏的放疗剂量与术后并发症无关。
  • 含紫杉类化疗方案与术后并发症发生率增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complications after esophagectomy are common and the possible increase in postoperative complications associated with neoadjuvant chemoradiotherapy is of concern. The aim of our study was to analyze if the addition of radiotherapy to neoadjuvant chemotherapy increases the incidence and severity of postoperative complications, including evaluation of the relation between radiation doses to the heart and lungs and postoperative complications. METHODS: The study was based on an institutional surgical database for esophageal cancer. The study period was October 2008 to March 2020. Patients treated with neoadjuvant chemoradiotherapy were compared to patients treated with neoadjuvant chemotherapy and dose/volume parameters for the lungs and heart considered. The primary outcome was 30-day postoperative complications. RESULTS: During the study period, 274 patients underwent surgery for esophageal cancer, 93 patients after neoadjuvant chemotherapy and 181 patients after neoadjuvant chemoradiotherapy. The median prescribed radiation dose to the planning target volume was 41.4 Gy, the median of the mean lung dose was 6.2 Gy, and the median of the mean heart dose was 20.3 Gy. The addition of radiotherapy to neoadjuvant chemotherapy did not increase the incidence of postoperative complications. Neither were radiation doses to the lungs and heart associated with postoperative complications. Taxane-based chemotherapy regimens were however associated with an increased incidence of postoperative complications. CONCLUSIONS: In our cohort, the addition of neoadjuvant radiotherapy to chemotherapy was not associated with postoperative complications. However, taxane-based chemotherapy regimens, with or without concomitant radiotherapy, were associated with postoperative complications.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ólafsdóttir HS, Dalqvist E, Onjukka E, et al. Postoperative complications after esophagectomy for cancer, neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy: A single institutional cohort study. Clin Transl Radiat Oncol. 2023. PMID: 36936472. doi:10.1016/j.ctro.2023.100610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。